142 related articles for article (PubMed ID: 34694152)
21. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
[TBL] [Abstract][Full Text] [Related]
23. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
[TBL] [Abstract][Full Text] [Related]
24. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
25. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
[TBL] [Abstract][Full Text] [Related]
26. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
27. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
28. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
29. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.
Arrieta O; Michel Ortega RM; Angeles-Sánchez J; Villarreal-Garza C; Avilés-Salas A; Chanona-Vilchis JG; Aréchaga-Ocampo E; Luévano-González A; Jiménez MA; Aguilar JL
J Exp Clin Cancer Res; 2009 Aug; 28(1):120. PubMed ID: 19709439
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
32. Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor.
Takeshita H; Yonese J; Fujii Y; Kawakami S; Komai Y; Ohkubo Y; Yamamoto S; Ishikawa Y; Seto Y; Ohyama S; Fukui I
Int J Clin Oncol; 2007 Dec; 12(6):485-7. PubMed ID: 18071871
[TBL] [Abstract][Full Text] [Related]
33. Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers.
De Latour B; Fadel E; Mercier O; Mussot S; Fabre D; Fizazi K; Dartevelle P
Eur J Cardiothorac Surg; 2012 Jul; 42(1):66-71; discussion 71. PubMed ID: 22290909
[TBL] [Abstract][Full Text] [Related]
34. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
35. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses.
Hendry WF; Norman AR; Dearnaley DP; Fisher C; Nicholls J; Huddart RA; Horwich A
Cancer; 2002 Mar; 94(6):1668-76. PubMed ID: 11920527
[TBL] [Abstract][Full Text] [Related]
36. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
Bosl GJ; Head MD
Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
[TBL] [Abstract][Full Text] [Related]
37. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.
Lorch A; Rick O; Wündisch T; Hartmann JT; Bokemeyer C; Beyer J
J Urol; 2010 Jul; 184(1):168-73. PubMed ID: 20483152
[TBL] [Abstract][Full Text] [Related]
38. The role of second-look surgery in the management of advanced germ cell malignancies.
Marina NM; Rao B; Etcubanas E; Jenkins JJ; Kun L; Thompson EI
Cancer; 1991 Jul; 68(2):309-15. PubMed ID: 1712663
[TBL] [Abstract][Full Text] [Related]
39. Postchemotherapy surgery in nonseminomatous testicular tumors.
Hornák M; Ondrus D; Matoska J; Cársky S
Eur Urol; 1996; 29(3):325-30. PubMed ID: 8740018
[TBL] [Abstract][Full Text] [Related]
40. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.
Horvath LG; McCaughan BC; Stockle M; Boyer MJ
Intern Med J; 2002 Mar; 32(3):79-83. PubMed ID: 11885847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
